title: Advocates call for long-term extension of the FDA's rare pediatric disease priority review program: Federal voucher program considered instrumental in shortening drug review, approval period.
mesh_terms: D002648:Child; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D035082:Federal Government; D006801:Humans; D035583:Rare Diseases / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*